HC Wainwright Raises Vericel (NASDAQ:VCEL) Price Target to $26.00

Vericel (NASDAQ:VCEL) had its price target boosted by HC Wainwright from $22.00 to $26.00 in a research report released on Thursday morning, The Fly reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock.

A number of other equities analysts have also weighed in on VCEL. Oppenheimer reiterated a buy rating and set a $32.00 target price on shares of Vericel in a research note on Monday, October 5th. ValuEngine upgraded Vericel from a hold rating to a buy rating in a research note on Monday, October 12th. Needham & Company LLC assumed coverage on Vericel in a research note on Wednesday, August 5th. They set a hold rating on the stock. BidaskClub upgraded Vericel from a hold rating to a buy rating in a research note on Tuesday, September 15th. Finally, SVB Leerink increased their target price on Vericel from $20.00 to $30.00 and gave the stock an outperform rating in a research note on Monday, October 12th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $25.00.

VCEL opened at $20.68 on Thursday. Vericel has a 12-month low of $6.78 and a 12-month high of $22.26. The stock has a market cap of $935.77 million, a price-to-earnings ratio of -2,068.00 and a beta of 2.88. The business has a 50 day moving average of $18.37 and a 200-day moving average of $15.36. The company has a quick ratio of 5.92, a current ratio of 6.39 and a debt-to-equity ratio of 0.19.

Vericel (NASDAQ:VCEL) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported ($0.18) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.21) by $0.03. The business had revenue of $20.00 million during the quarter, compared to analyst estimates of $19.31 million. The business’s quarterly revenue was down 23.7% on a year-over-year basis. During the same period in the previous year, the business earned ($0.05) earnings per share. As a group, analysts expect that Vericel will post -0.17 earnings per share for the current year.

A number of institutional investors have recently bought and sold shares of VCEL. AJO LP bought a new position in Vericel during the 2nd quarter worth $71,000. Private Advisor Group LLC bought a new position in Vericel during the 2nd quarter worth $73,000. Invesco Ltd. bought a new position in Vericel during the 1st quarter worth $100,000. Jane Street Group LLC bought a new position in Vericel during the 1st quarter worth $104,000. Finally, Advisory Services Network LLC boosted its holdings in shares of Vericel by 623.3% in the 2nd quarter. Advisory Services Network LLC now owns 10,850 shares of the biotechnology company’s stock valued at $150,000 after purchasing an additional 9,350 shares in the last quarter. Hedge funds and other institutional investors own 94.98% of the company’s stock.

Vericel Company Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.

Featured Story: How is an ETF different from a mutual fund?

The Fly

Analyst Recommendations for Vericel (NASDAQ:VCEL)

Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.